Clinical Trial Update: Subcutaneous Abatacept in Renal Transplant Recipients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating subcutaneous abatacept in kidney transplant recipients has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Transplantation

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Idelberto Badell | Conditions: Kidney Transplant Recipient | Phase 1 | Status: COMPLETED | Results posted: 2026-04-03